OneSource Specialty Pharma Ltd

AI
OneSource Speci. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents
AI

OneSource Specialty Pharma Ltd

₹ 1,459 -0.81%
13 Oct - close price
onesourcecdmo.com BSE: 544292 NSE: ONESOURCE
About

Incorporated in 2007, OneSource Specialty Pharma Ltd is in the research, development, manufacture and commercialisation of bio
logical drug products in various injectable formats. It also offers end-to-end CDMO
services across all phases of pre-clinical
and clinical development and commercial
supply of biologics[1]

Key Points

Business Overview:[1]
OSSPL is a subsidiary of Strides Pharma
Ltd. The company is a Contract Development
and Manufacturing Organisation that caters
to several biopharma and biotech companies.
It covers the entire CDMO value chain, from clinical development to technology transfer
to commercial manufacture and regulatory assistance.

Website BSE NSE
  • Market Cap ₹ 16,766 Cr.
  • Current Price ₹ 1,459
  • High / Low ₹ 1,925 / 1,057
  • Stock P/E
  • Book Value ₹ 509
  • Dividend Yield 0.00 %
  • ROCE 0.59 %
  • ROE -1.09 %
  • Face Value ₹ 1.00
Edit ratios

Pros

Cons

  • Stock is trading at 2.87 times its book value
  • Company has low interest coverage ratio.
  • Company has a low return on equity of -2.63% over last 3 years.
  • Promoters have pledged 37.2% of their holding.
  • Company has high debtors of 177 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of Nifty MidSmallcap 400 Nifty Smallcap 50 Nifty MidSmallcap400 50:50 Nifty 500 Multicap 50:25:25 Nifty 500

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
34 56 73 292 334 393 426 327 376 290 428 449
72 67 76 228 257 251 243 239 269 273 336 326
Operating Profit -39 -10 -3 64 77 142 183 88 106 17 92 123
OPM % -114% -19% -3.8% 22% 23% 36% 43% 27% 28% 6% 21% 27%
-32 -74 3 -1 -1 -94 2 2 3 -2 2 -0
Interest 25 26 20 42 45 46 33 27 34 38 23 31
Depreciation 18 20 20 68 68 69 68 68 70 70 72 72
Profit before tax -114 -130 -40 -47 -37 -67 83 -4 6 -93 -0 20
Tax % 0% 0% 0% -88% 12% 4% -19% -96% -83% -5% -1,630% -23%
-114 -130 -40 -6 -42 -69 98 -0 10 -89 5 25
EPS in Rs -6.02 8.61 -0.02 0.92 -7.74 0.40 2.18
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
21 132 39 172 1,445 1,422 1,543
93 229 199 254 978 1,117 1,204
Operating Profit -71 -97 -161 -82 467 304 339
OPM % -334% -73% -415% -48% 32% 21% 22%
1 4 -526 -143 -94 5 2
Interest 16 68 48 89 166 122 126
Depreciation 34 70 66 76 274 279 283
Profit before tax -121 -231 -800 -391 -68 -92 -67
Tax % 0% -0% 0% 0% -73% -20%
-121 -231 -800 -391 -18 -74 -49
EPS in Rs -1.57 -6.44 -4.24
Dividend Payout % 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: 131%
3 Years: 232%
TTM: 4%
Compounded Profit Growth
10 Years: %
5 Years: 8%
3 Years: 24%
TTM: -142%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: -21%
Return on Equity
10 Years: %
5 Years: -10%
3 Years: -3%
Last Year: -1%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 2 3 4 4 11 11
Reserves 774 1,009 781 392 5,869 5,820
386 1,154 864 562 772 1,276
96 276 365 468 1,005 1,197
Total Liabilities 1,258 2,442 2,015 1,426 7,657 8,304
633 1,231 1,361 863 6,118 6,017
CWIP 431 490 334 188 218 529
Investments 0 0 4 20 16 16
195 722 314 356 1,305 1,742
Total Assets 1,258 2,442 2,015 1,426 7,657 8,304

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
-118 -416 -163 -107 -68 9
-207 -692 -68 511 -201 -495
381 1,162 118 -391 412 359
Net Cash Flow 56 54 -112 13 143 -127
Free Cash Flow -325 -1,071 -207 -171 -196 -561
CFO/OP 164% 430% 108% 130% -13% 6%

Ratios

Consolidated / View Standalone

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 38 65 36 117 105 177
Inventory Days 87 1,805 615 258 222 438
Days Payable 762 410 420 163 147 307
Cash Conversion Cycle -637 1,461 232 212 180 308
Working Capital Days -2,392 -1,291 -6,745 -877 -58 -6
ROCE % -10% -12% -12% 6% 1%

Insights

In beta
Dec 2023 Mar 2025 Mar 2026 Mar 2027 (P) Mar 2028 (P)
Cartridge Installed Capacity (DDC)
Million units per year

Log in to view insights

Please log in to see hidden values.

Login
Successful Regulatory and Customer Audits (Annual)
Count
Total Customers (Global)
Count
DDC Projects (Cumulative)
Count
Device Platforms (DDC)
Count
New MSAs / Licensing Agreements Signed (Annual)
Count
Soft Gelatin Capsule Installed Capacity
Billion units per year
Sterile Production Days Available (Annual)
Days per year

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
37.76% 34.25% 29.78% 29.77% 29.93% 30.48% 30.48%
17.44% 18.54% 18.69% 19.39% 19.24% 17.50% 19.19%
12.56% 18.03% 18.09% 18.48% 18.80% 20.61% 23.37%
32.24% 29.17% 33.42% 32.34% 32.01% 31.40% 26.95%
No. of Shareholders 98,42582,71287,76087,41684,59579,46077,899

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls